Xcout Intel
Grey Wolf Therapeutics
Grey Wolf Therapeutics is a biotechnology company headquartered in the UK focused on delivering a new class of treatments to improve the lives of people with cancers and autoimmune disorders.
Subscribe to see Grey Wolf Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Grey Wolf Therapeutics at a glance
Grey Wolf Therapeutics is a biotechnology company headquartered in United Kingdom. Its most recent funding round, Series B, raised $50M in May 2024. Xcout tracks 16 named people at Grey Wolf Therapeutics, including Paul Stainer (Chief Operating Officer).
Grey Wolf Therapeutics leadership
- Paul StainerChief Operating Officer
- Andy PageChief Business Officer
- Tom LillieChief Medical Officer
- Peter JoyceChief Executive Officer & Co-founder
- Tom McCarthyNon-Executive Director & Co-founder
- James DodsonHead of People
10 more named people on record for Grey Wolf Therapeutics, with roles, board committees and tenure — see the full roster →
Grey Wolf Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $50M | 8 named | |
| Series B | $49M | — | |
| — | $3.3M | — | |
| — | $14M | 7 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Grey Wolf Therapeutics competitors
A few of Grey Wolf Therapeutics's closest competitors — see the full list of competitors and alternatives →
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Oxford BioTherapeutics is a clinical-stage oncology company focused on developing first-in-class cancer therapeutics with a proprietary pipeline. The company operates from locations in Oxford, United Kingdom, as well as San Jose, California, and Morristown, New Jersey, in the United States.
Nimbus Therapeutics is a biotechnology company that uses structure-based drug discovery and computational chemistry to develop small-molecule medicines. It focuses on therapeutic areas including oncology, autoimmune disease, and metabolic disorders, serving patients through internally developed programs and pharmaceutical partnerships.
ImCheck Therapeutics designs and develops next-generation immunotherapeutic antibodies focused on modulating the immune system through the butyrophilin and butyrophilin-like superfamily of checkpoint molecules. The company's pipeline targets treatments for cancer, infectious disease, and autoimmune disease.
AbolerIS Pharma is a pre-clinical stage biotech company founded in Nantes, France, specializing in the development of innovative immunomodulators and advanced biopharmaceuticals for autoimmune conditions.
Canopy Immuno-Therapeutics is a pre-clinical stage biotechnology company based in Haifa, Israel, focused on developing non-immunosuppressive biologics, including Antigen-Drug Conjugates, for antibody-mediated autoimmune conditions.
Get Grey Wolf Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Grey Wolf Therapeutics in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- 4 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access